Comvita and Derma strike new Medihoney deals

16 January 2017 - Deborah Wilkes

Archived

Comvita has sold the Medihoney wound care brand to its long-term partner in the US, Derma Sciences, for USD13.3 million in cash plus a potential earnout of USD5.0 million. Derma Sciences is outlicensing the worldwide OTC rights for Medihoney to Comvita, and will continue to manufacture honey-based products for Comvita.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: